1 / 33

Management of Testicular Cancer

Management of Testicular Cancer. Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr. Testicular cancer :1% male neoplasms , 5% urological tumours, incidence 3-10 /100,000 per year in West

jessica-mitchell
Download Presentation

Management of Testicular Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr

  2. Testicular cancer :1% male neoplasms , 5% urological tumours, incidence 3-10 /100,000 per year in West • Risk factors : cryptorchidism, Klinefelter’s syndrome, family history, contralateral tumor, and infertility • Germ cell tumors constitutes 95% of testicular tumors • Testicular tumours show excellent cure rates. • proper staging • chemotherapeutic combinations • early treatment-based radiotherapy and surgery • strict follow-up & salvage therapies

  3. STAGING Of TESTICULAR CANCER

  4. Staging – AJCC (American Joint Comittee on Cancer) • Stage 0 – CIS • Stage I – T1-4/N0/M0 • IA – T1 • IB – T2-4 • IS – ANY T, S1-3 • Stage II – T1-4/N1-3/M0 • IIA – N1 • IIB – N2 • IIC – N3 • Stage III – T1-4/N1-3/M1

  5. Tumour Markers • Alpha-fetoprotein • Trophoblasts • Major serum binding protein produced by foetal yolk sac, liver, GIT • Negligible amounts after 1 year of age • T1/2 :4-6 days • Beta-human chorionicgonadotrophin • Syncytiotrophoblasts • Secreted by placenta for maintanence of corpus luteum • T1/2:24 hours • LDH • tumour burden

  6. GERM CELL TUMORS • Seminoma : • Typical/Classic (82 – 85 % of seminomas) • Spermatocytic (2 – 12 % of seminomas)—extremely low metastatic potential. Men>50years • Anaplastic previously classified as separate entity that was believed to be more aggressive/lethal due to greater mitotic activity. However, mitotic index is not associated with worse prognosis, so term no longer used • Nonseminomatous Germ Cell Tumors Embryonal cell carcinoma Yolk sac tumor Teratoma Choriocarcinoma • Mixed Tumors • Intratubular germ cell neoplasia (CIS)

  7. Frequency of Histologic causes: GCT constitute 90 – 95% of all primary testicular malignancies Seminoma: 30 – 60% Embryonal carcinoma: 3- 4 % in pure form (present in 40% of NSGCTs) Teratoma: 5 – 10% Pure choriocarcinoma: 1% Mixed GCTs: 60%

  8. PATTERNS OF SPREAD OF GCTs • Right testis : - Interaortocaval nodes at level of 2nd vertebral body • Left testis : Left paraaortic and preaortic nodes (bounded by left ureter, left renal vein, aorta and origin of IMA) • Cross-over: Right to left (but NOT left to right) • Epididymis: external iliac chain • Inguinal node mets may occur if: Scrotal involvement of primary tumor Prior inguinal or scrotal surgery Retrograde lymphatic spread from massive retroperitoneal LN deposits

  9. STAGE I SEMINOMA • The overall CSS rate under surveillance : 97-100% for seminoma stage I . • The drawback of surveillance :intensive follow-up, repeated imaging of the retroperitoneal lymph nodes, for at least 5 years after orchidectomy • There was no significant difference between one cycle of carboplatin compared to adjuvant radiotherapy, with regard to recurrence rate, time to recurrence, and survival after a median follow-up of 4 years • Adjuvant radiotherapy to a para-aortic field or to a hockeystick field , with moderate doses (total 20-24 Gy), will reduce the relapse rate to 1-3%

  10. SURVEILLANCE FOR STAGE I SEMINOMA • H& PE ,serum tumor markers (bhCG, LDH, AFP) every 3-4 months the first year, every 6 months the second year, then annually thereafter • Imaging: Chest radiography each visit; CT scan of the pelvis annually for 3 years if status post para-aortic radiotherapy

  11. STAGE IIA-B SEMINOMA • 15 to 20 percent of seminoma patients have CS II disease, 70% of whom have CS IIA-B. Dog-leg radiotherapy using 25 to 30 Gy is employed at most centers • Long-term disease-free survival rates are 92% to 100% for CS IIA and 87% to 90% for CS IIB , with in-field recurrences reported in 0% to 2% and 0% to 7% of cases, respectively • Relapses are cured in virtually all cases with first-line chemotherapy, and disease-specific survival approaches 100% • Induction chemotherapy using first-line regimens (BEP×3 or EP×4) is an accepted alternative to dog-leg radiotherapy for patients with bulky (>3 cm) and/or multiple retroperitoneal masses because the risk of relapse is lower than with dog-leg radiotherapy (15% and 30% of CS IIA and IIB patients in one center)

  12. Surveillance for stage IIa/b seminoma • H& PE and serum tumor markers every 3-4 months in years 1-3, every 6 months in year 4, and then annually thereafter • Imaging: Radiography each visit; CT scan of the abdomen and pelvis during month 4 of the first year

  13. STAGE IIC AND III • Patients with CS IIC and III seminoma are treated with induction chemotherapy • Ninety percent of patients with advanced seminoma are classified as good risk and should receive either BEP×3 or EP×4 chemotherapy • Complete radiographic responses are reported in 70% to 90% of patients, and the 5-year overall survival is 91% • With BEP×4 chemotherapy, the 5-year overall and progression-free survival is 79% and 75%, respectively

  14. Surveillance for stage IIc, III seminoma • H& PE and serum tumor markers every 2 months the first year, every 3 months the second year, every 4 months the third year, every 6 months the fourth year, and then annually thereafter • Imaging: Chest radiography each visit; CT scan of the abdomen and pelvis during month 4 of the first year status post surgery (otherwise, every 3 months until stable); PET scan as clinically indicated

  15. Follow Up - Seminoma

  16. Relapses • Surveillance/Radiotherapy • BEP x 3 • Chemotherapy cohort • VIP x 4 (vinblastine, ifosfamide and cisplatin) or • TIP x 4 (paclitaxol, ifosfamide and cisplatin)

  17. Prognostic factors for occult metastatic disease in testicular cancer

  18. Impact on fertility and fertility-associated issues • In patients in the reproductive age group, pre-treatment fertility assessment (testosterone, LH and FSH levels) should be performed, and semen analysis and cryopreservation should be offered. • If cryopreservation is desired, it should preferably be performed before orchidectomy, but in any case prior to chemotherapy treatment • In cases of bilateral orchidectomy or low testosterone levels after treatment of TIN, life-long testosterone supplementation is necessary • Patients with unilateral or bilateral orchidectomy should be offered a testicular prosthesis

  19. Non Sminoma Germ Cell Tumors • Approximately one third of NSGCT patients have CS I with normal postorchiectomy levels of serum tumor markers • The optimal management of these patients continues to generate controversy because the long-term survival associated with surveillance, RPLND, and primary chemotherapy approaches 100% • Up to 30% of NSGCT patients with clinical stage I (CS1) disease have subclinical metastases and will relapse if surveillance alone is applied after orchidectomy.

  20. Surveillance In NSGCT CS1 • Close surveillance after orchidectomy in CS1 NSGCT patients showed a cumulative relapse rate of ~30%, with 80% of relapses occurring during the first 12 months of follow-up, 12% during the second year and 6% during the third year, decreasing to 1% during the fourth and fifth years • 35% of relapsing patients have normal levels of serum tumour markers at relapse. 60% of relapses are in the retroperitoneum • Despite very close follow-up, 11% of relapsing patients presented with large-volume recurrent disease. • surveillance within an experienced surveillance programme may be offered to patients with non-risk stratified clinical stage I non-seminoma as long as they are compliant and informed about the expected recurrence rate as well as the salvage treatment

  21. Follow Up – Surveillance Stage I NSGCT

  22. Primary chemotherapy In NSGCT CS1 • Several studies involving two courses of chemotherapy with cisplatin, etoposide and bleomycin (PEB) as primary treatment for high-risk patients (having ~50% risk of relapse) have been reported . • In these series, involving > 200 patients, some with a median follow-up of nearly 8 years , a relapse rate of only 2.7% was reported, with very little long-term toxicity • Two cycles of cisplatin-based adjuvant chemotherapy do not seem to adversely affect fertility or sexual activity • slow-growing retroperitoneal teratomas after primary chemotherapy

  23. Retroperitoneal lymph node dissection • If RPLND done, ~30% have lymph node involvement, pathological stage II (PS2) disease . RPLND -> -ve L.N (PS1), ~10% of the PS1 patients relapse at distant sites. • The main predictor of relapse in CS1 NSGCT managed by surveillance, for having PS2 disease and for relapse in PS1 after RPLND- vascular invasion in the primary tumour . • Patients without vascular invasion constitute ~50-70% of the CS1 population, and these patients have only a 15-20% risk of relapse on surveillance, VS 50% relapse rate in patients with vascular invasion

  24. The risk of relapse for PS1 patients is < 10% for those without vascular invasion and ~30% for those with vascular invasion • If two (or more) courses of cisplatin-based chemotherapy are given adjuvant to RPLND in PS2 cases, the relapse rate is reduced to < 2%, including teratoma relapse . • The risk of retroperitoneal relapse after a properly performed nerve-sparing RPLND is very low (< 2%), as is the risk of ejaculatory disturbance or other significant side-effects

  25. In a randomised comparison of RPLND with one course of PEB chemotherapy, adjuvant chemotherapy significantly increased the 2-year recurrence-free survival to 99.41% as opposed to surgery, which had a 2-year recurrence-free survival of 92.37% • It was also found that one adjuvant PEB reduced the number of recurrences to 3.2% in the high-risk and to 1.4% in the low-risk patients

  26. CS1S with (persistently) elevated serum tumour markers • If the marker level increases after orchidectomy, the patient has residual disease. If RPLND is performed, up to 87% of these patients have pathological finding in the nodes . • An U/S of the contralateral testicle must be performed, if this was not done initially. • The treatment of true CS1S patients is still controversial. They may be treated with three courses of primary PEB chemotherapy and with follow-up as for CS1B patients (high risk) after primary chemotherapy, or by RPLND . • The presence of vascular invasion may strengthen the indication for primary chemotherapy as most CS1S with vascular invasion will need chemotherapy sooner or later

  27. PS – pathologic stage,PD – progressive disease, NC – no change

More Related